Search results for "coagulants"

showing 10 items of 248 documents

Cryptogenic stroke and atrial fibrillation in a real-world population: the role of insertable cardiac monitors

2020

AbstractThe incidence of atrial fibrillation (AF) in cryptogenic stroke (CS) patients has been studied in carefully controlled clinical trials, but real-world data are limited. We investigated the incidence of AF in clinical practice among CS patients with an insertable cardiac monitor (ICM) placed for AF detection. Patients with CS admitted to our Stroke Unit were included in the study; they received an ICM and were monitored for up to 3 years for AF detection. All detected AF episodes of at least 120 sec were considered. From March 2016 to March 2019, 58 patients (mean age 68.1 ± 9.3 years, 67% male) received an ICM to detect AF after a CS. No patients were lost to follow-up. AF was detec…

Malelcsh:MedicineKaplan-Meier Estimate030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factorslcsh:ScienceStrokeMultidisciplinaryIncidence (epidemiology)QRNeuro-vascular interactionsAtrial fibrillationICM deviceStrokeTreatment OutcomeCardiologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptommedicine.medical_specialtyScienceNeurophysiologyCryptogenic strokeAsymptomaticArticleProsthesis ImplantationLoop recorder03 medical and health sciencesInternal medicinemedicineHumansAgedMonitoring Physiologicbusiness.industrylcsh:RAnticoagulantsmedicine.diseaseAtrial fibrillationClinical trialCryptogenic strokeAnticoagulant therapyElectrocardiography AmbulatoryCardiac monitorslcsh:Qbusiness030217 neurology & neurosurgeryFollow-Up StudiesScientific Reports
researchProduct

Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study

2011

The synthetic arginine-derived direct thrombin inhibitor argatroban is an attractive anticoagulant for percutaneous coronary intervention (PCI), because of its rapid onset and offset, and its hepatic elimination. Argatroban was approved for PCI in patients with heparin-induced thrombocytopenia (HIT). However, there are limited data about argatroban in non-HIT patients. The objective of this open-label, multiple-dose, controlled study was to examine the safety and efficacy of argatroban in patients undergoing elective PCI.Of 140 patients randomized to three argatroban dose groups (ARG250, ARG300, and ARG350 with 250, 300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/kg/min infusion) and …

Malemedicine.drug_classmedicine.medical_treatmentActivated clotting timeHemorrhageArginineAntithrombinsArgatrobanBolus (medicine)medicineHumansAngina UnstableMyocardial infarctionAngioplasty Balloon CoronaryBlood CoagulationAgedSulfonamidesDose-Response Relationship Drugmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantAnticoagulantsPercutaneous coronary interventionThrombosisMiddle Agedmedicine.diseaseDirect thrombin inhibitorPipecolic AcidsAnesthesiaConventional PCIFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugInternational Journal of Cardiology
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program

2014

Summary Background Depressive symptoms have detrimental effects on quality of life and mortality. Poor adherence to a treatment regimen is a potential mechanism for the increased risk of adverse medical events associated with depression. Regarding oral anticoagulation with vitamin K antagonists, adherence is crucial for the outcome. Little is known about the clinical relevance of current depressiveness for anticoagulation treatment. Objectives To examine the impact of current depressiveness on anticoagulation treatment in regular medical care. Patients/Methods We examined the association between clinically significant depressiveness as assessed by the Patient Health Questionnaire-2 ≥ 2 (PHQ…

Malemedicine.medical_specialtyCross-sectional studyAdministration OralHealth literacyMedication AdherenceCohort StudiesPatient satisfactionQuality of lifeAmbulatory careSurveys and QuestionnairesInternal medicineAmbulatory CarePrevalenceHumansMedicineClinical significanceInternational Normalized RatioDepression (differential diagnoses)AgedDepressionbusiness.industryAnticoagulantsHematologyMiddle AgedCross-Sectional StudiesTreatment OutcomePatient SatisfactionMultivariate AnalysisPhenprocoumonQuality of LifePhysical therapyFemalebusinessCohort studyJournal of Thrombosis and Haemostasis
researchProduct

High incidence of venous thrombosis after surgery for abdominal aortic aneurysm

2009

Objective The incidence of venous thromboembolism (VT) after aortic abdominal aneurysm (AAA) surgery is imprecisely reported. On one hand, thromboprophylaxis has improved, on the other hand, AAA patients have become older and/or present worse comorbidities. Herein, we prospectively analyzed the incidence of VT in a continuous series of patients operated on for AAA repair and looked for predictive factors. Materials and Methods Between January 1, 2005, and December, 31, 2006, 193 consecutive patients (177 men and 16 women), mean age 73 (range, 47-93) underwent elective AAA repair, 137 open (71%) and 56 endovascular (29%), in our institution. Thromboprophylaxis consisted of thigh-length compr…

Malemedicine.medical_specialtyDeep veinDrug Administration ScheduleAortic aneurysmRisk FactorsmedicineHumansProspective StudiesEnoxaparinEarly AmbulationAgedUltrasonographyAged 80 and overVenous Thrombosisbusiness.industryHeparinIncidenceAnticoagulantsTransfusion ReactionPerioperativeVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisAbdominal aortic aneurysmSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeAnesthesiaSurgeryFemaleFresh frozen plasmaCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresStockings CompressionAbdominal surgeryAortic Aneurysm AbdominalJournal of Vascular Surgery
researchProduct

Measuring functional limitations after venous thromboembolism: A call to action.

2019

The main objectives of therapeutic trials in venous thromboembolism (VTE) are to prevent recurrent VTE, major bleeding and death. While these outcomes are indeed highly relevant, they are also rare and do not fully capture the overall functional outcome of VTE patients. Importantly, functional limitations after VTE are prevalent after both deep vein thrombosis and pulmonary embolism occurring in up to 50% of patients. These post-VTE syndromes are associated with a decreased quality of life, higher risk of depressive disorders, unemployment and increased utilization of healthcare resources. Because of the major impact of functional limitations on individual patients and society as a whole, d…

Malemedicine.medical_specialtyDeep veinMann Whitney U test030204 cardiovascular system & hematologyValue-based healthcare03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Postthrombotic syndromeRisk FactorsDeep vein thrombosisHealth carepulmonary hypertensionmedicineHumanscardiovascular diseasesIntensive care medicineVenous Thrombosisbusiness.industryPulmonary embolismActivities of daily livingAnticoagulantsHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesClassificationThrombosisCall to actionPulmonary embolismClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisScale (social sciences)FemalebusinessThrombosis research
researchProduct

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baselin…

2021

Abstract Introduction Sex and the presence of specific provoking risk factors, along with age, influence the presentation and prognosis of venous thromboembolism (VTE). We investigated the presentation, course and quality of life in women and men with acute VTE classified according to their VTE provoking factors. Methods PREFER in VTE is an international, non-interventional registry of patients with a first episode of acute symptomatic VTE. Baseline provoking factors were classified as follows: major transient, minor transient, active cancer, and none identifiable. The primary outcome was recurrent VTE. Quality of life and treatment satisfaction were secondary outcomes. Results Of 3,455 pat…

Malemedicine.medical_specialtyEpidemiology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceInternal medicineDeep vein thrombosisEpidemiologyInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineFirst episodeSex Characteristicsbusiness.industry10031 Clinic for AngiologyAbsolute risk reductionCancerAnticoagulantsVenous Thromboembolismequipment and suppliesmedicine.diseaseSex specificNeoplasm RecurrenceRisk factorsLocal2724 Internal MedicineQuality of LifeSexFemalePresentation (obstetrics)Neoplasm Recurrence LocalbusinessVenous thromboembolism
researchProduct

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study

2016

Introduction Pharmacokinetic (PK) studies on recombinant FIX concentrate, Nonacog alpha, were conducted with different sampling time designs which gave rise to not complete and homogenous outcomes. In addition, patient's FIX genotype/PK relationship has never been investigated. Aim Investigate how different sampling times may affect PK parameters and try to find a FIX genotype/PK relationship. Patients and Methods A cohort pharmacokinetic, Nonacog Alpha single-dose, open-label, non-comparative study was conducted in eight Comprehensive Care Haemophilia Centres in Italy. Seventeen previously treated moderate or severe haemophilia B patients were enrolled. Factors IX:C one-stage clotting assa…

Malemedicine.medical_specialtyGenotypeMutation MissensePharmacokinetic030204 cardiovascular system & hematologyPharmacologyHaemophiliaGastroenterologyHemophilia BDrug Administration ScheduleCohort StudiesFactor IX03 medical and health sciences0302 clinical medicinePharmacokineticsDNA Recombinant proteinInternal medicineHaemophilia BGenotypemedicineHumansHaemophilia BGenetics (clinical)Volume of distributionClotting factorbusiness.industryCoagulantsArea under the curveGeneral MedicineHematologymedicine.diseaseRecombinant ProteinsItalyROC CurveCodon NonsenseArea Under Curvebusinesspharmacokinetics030215 immunologyBlood samplingHalf-Life
researchProduct

Studies on the disposition, metabolism and hepatotoxicity of coumarin in the rat and Syrian hamster.

2002

The hepatotoxicity, metabolism and disposition of coumarin has been compared in male Sprague-Dawley rats and Syrian hamsters. The treatment of rats for 12, 24 and 42 weeks with diets containing 0.2 and 0.5% coumarin resulted in hepatotoxicity and increased relative liver weights. While levels of cytochrome P450 (CYP) and CYP-dependent enzymes were decreased, levels of reduced glutathione (GSH) and activities of UDP glucuronosyltransferase, gamma-glutamyltransferase and GSH S-transferase were increased. In contrast, coumarin produced few hepatic changes in the Syrian hamster. Following a single oral dose of 25 mg/kg [3-14C]coumarin, radioactivity was rapidly excreted by the rat and Syrian ha…

Malemedicine.medical_specialtyHamsterToxicologyRats Sprague-Dawleychemistry.chemical_compoundCytosolPharmacokineticsLiver Function TestsSpecies SpecificityOral administrationCoumarinsInternal medicineCricetinaemedicineToxicokineticsAnimalsheterocyclic compoundsTissue DistributionNutritionbiologyMesocricetusBody WeightCytochrome P450AnticoagulantsGeneral MedicineGlutathioneOrgan SizeCoumarinGlutathioneDietRatsEndocrinologychemistryLiverToxicitybiology.proteinChemical and Drug Induced Liver InjuryOxidation-ReductionFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct